Paid donation and plasma trade: Unrecognized forces that drive the AIDS epidemic in developing countries

International Journal of STD and AIDS

Volumn 16, Issue 1, 2005, Pages 5-8

  Volkow, Patricia ^a   Del Rio, Carlos ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Commercial plasmapheresis; HIV; Paid plasma donor

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD DONOR; BLOOD TRANSFUSION; DRUG INDUSTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PLASMA; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BLOOD BANKS; BLOOD DONORS; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; EQUIPMENT CONTAMINATION; HUMANS; PLASMAPHERESIS;

EID: 13244294170     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462052932638     Document Type: Review

References (73)

1. Volkow P. Plasma paid donors, a risk group for HIV transmission not fully recognized. J Acquir Immune Defic Syndr 1990;5:949
2. Alvarez Suarez Y, Marín-López A, Lobato-Mendizabal E, Galidno-Rodriguez G. Donadores sanguíneos remunerados: un nuevo grupo de riesgo para el desarrollar SIDA en México. Salud Publica Mex 1989;31:642-4
3. Rivero RA, Santos G, Velasco A, Jiménez-Prada M, Dueñas A. Donantes retribuidos de plasma e infección por el virus de la inmunodeficiencia humana. Un nuevo grupo de riesgo para SIDA? Rev Clin Esp 1990;186:310-1
4. Volkow P, Perez-Padilla R, del Río C Ch, Mohar A. Possible role of commercial plasmapheresis banks on the AIDS epidemic in México. Rev Invest Clin 1998;50:221-6
5. Volkow P, Mohar A, Terrazas JJ, et al. Changing risk factors for HIV infection in Mexican women. Arch Med Res 2002;33:61-6
6. Volkow P, Velasco SR, Muller N, et al. Transfusion-associated HIV infection in Mexico related to paid blood donors; HIV epidemic. Int J STD AIDS 2004;15:337-42
7. Sepúlveda JA, García LG, Dominguez-Torix JL, Valdespino JL. Prevention of HIV transmission through blood and blood products: experience in Mexico. Bull Pan AMM Health Organ 1989;23:108-14
8. Sepúlveda AJ, García LG, Domínguez TJ, Valdespino JG. Preventión de la Transmisión sanguínea del VIH. La experiencia mexicana. En SIDA Perfil de una epidemia. Washington, DC: Organización Panamericana de la Salud, Mexico. 1989;163-72
9. Sepúlveda JA, del Rio AZ, Valdespino JL, García LG, Velazquez-Velazquez L, Volkow P. La estrategia de prevensión de la transmisión del VIH/SIDA a través de la sangre y sus derivados en México. Salud Pública Mex 1995;37:624-35
10. Volkow P, Marin Lopez A, Torres I. Plasma trade and the HIV epidemic. Lancet 1997;349:327-8
11. Centers for Disease Control. Plasmapheresis-associated hepatitis A outbreak in South Carolina. MMWR 1997;23:274-5
12. Centers for Disease Control. Plasmapheresis-associated hepatitis. MMWR 1974;23:13-19
13. Guyer B, Bradley DW, Bryan JA, Maynard JE. Non-A Non-B hepatitis among participants in a plasmapheresis stimulation program. J Infect Dis 1979;139:634-40
14. Avila C, Stetler H, Sepulveda J, et al. The epidemiology of HIV transmission among paid donors, Mexico City, Mexico. AIDS 1989;3:631-3
15. Meng ZD, Sun YD, Chen XR, et al. A serological study of hepatitis C infection in plasmapheresis donors. Chin Med J 1991;104:494-7
16. Zhang WH, Liu ChB, Alter HJ, Shih JWK. Hepatitis C virus causing non-A, non-B hepatitis in plasmapheresis centre. Lancet 1990;335:353
17. Wu Z, Liu Z, Detels R. HIV-infection in commercial plasma donors in China. Lancet 1995;346:61-2
18. Datz C, Cramp M, Haas T, et al. The natural course of Hepatitis C virus infection 18 years after an epidemic oubreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999;44:563-7
19. Navarro V, Roig P, Nieto A, et al. A small outbreak of HIV infection among commercial plasma donors. Lancet 1988;ii:42
20. Banerjee K, Rodrigues J, Kulkarni S, Israel Z, Thakar M. Outbreak of HIV seropositivity among commercial plasma donors in Pune, India. Lancet 1989;ii:166
21. Sing YN, Chandra M, Nanu A, Bhasin R, Kapoor S, Malaviya AN. HIV infection in blood donors of Delhi, India: 11/2 years' experience. J AIDS 1991;4:1008-9
22. Viana-Martins FS. Malaria induzida no estado do Rio de Janeiro MSc thesis Federal University of Rio de Janeiro, 1986
23. Muss N, Frösner G, Sandhofer F. Epidemic outbreak of a non-A, non-B hepatitis in a plasmapheresis center. Epidemiological observation. Infection 1985;2:57-80
24. Laskus T, Ciancciara J, Slusarczyk J. Follow-up of NANB hepatitis outbreak in plasmapheresis unit. Lancet 1989;i: 387-91
25. Gibbs WN, Corcoran P. Blood safety in developing countries. Vox Sang 1994;67:377-81
26. Smith DK, Curran JW. The international epidemiology of HIV infection In: Madhok R, Forbes CD, Evatt BL, eds. Blood, Blood Products and HIV 2nd edn. Cambridge: Chapman & Hall Medical/University Press, 1994;1-37
27. Weinberg PD, Hounshell J, Sherman LA, et al. Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s. Ann Intern Med 2002;136:312-19
28. Craske J, Kirk P, Cohen B, Vandervelde EM. Commercial factor VIII associated hepatitis, 1974-1975, in the United Kingdom. A retrospective survey. J Hyg Camb 1978;80:327-36
29. Anonimo Outbreak of Hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-1994. MMWR 1994;43:505-9
30. Yu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD. C transmission associated with intravenous gammaglobuline. Lancet 1995;345:1173-4
31. Healey CJ, Sabharwal NK, Daub J, et al. Outbreak of acute Hepatitis C following the use of anti-C virus - screened intravenous immunologulin therapy. Gastroenterology 1996;110:1120-6
32. Echeverria JM, Leon P, Domingo CJ, et al. Laboratory diagnosis and molecular epidemiology of an outbreak of Hepatitis C virus infection among recipients of human intravenous immunoglobulin in Spain. Transfusion 1996;36:725-30
33. Smith DB, Lawlor E, Power J, et al. A second outbreak of Hepatitis C virus infection from anti-D immunoglobulin in Ireland. Vox Sang 1999;76:175-80
34. Lawlor E, Power J, Garson J, et al. Transmission rates of Hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation. Vox Sang 1999;76:138-43
35. Lefrere JJ, Loiseau P, Martinot-Peignoux M, et al. Infection by Hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion 1996;36:4-7
36. Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of Hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1900;76:254-6
37. Schramm W, Roggendorf M, Rommel F, et al. Prevalence of antibodies to hepatitis C (HCV) in haemophiliacs. Blut 1989;59:390-2
38. Pistello M, Ceccherini-Nelli L, Cecconi N, Bendinelli M, Panicucci F. Hepatitis C virus seroprevalence in Italian haemophiliacs injected with virus-inactivated concentrates: five year follow-up and correlation with antibodies to other viruses. J Med Virol 1991;33:43-6
39. Maisonneuve P, Laurian Y, Noel, et al. Antibodies against hepatitis C virus in French hemophiliacs. Rev Fr Transfus Hemobiol 1990;33:375-7
40. Blanchette VS, Vorstman E, Shore A, et al. Hepatitis C infection in children with hemophilia A and B. Blood 1991;78:285-9
41. Lane RS. Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet 1983;ii:974-5
42. Ochs HD, Fischer SH, Virant FS, Lee ML, Kingdom HS, Wedgwood RJ. Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet 1985;i:404-5
43. Lever AM, Webster ADB, Brown D, Thomas HC. Non-A, non-B hepatitis occurring in agammaglobulinemic patients after intravenous immunoglobulin. Lancet 1984;ii: 1062-1
44. Weiland O, Mattson L, Glauman H. Non-A, non-B hepatitis after intravenous immunoglobulin. Lancet 1986;i:976-7
45. Peerlinck K, Vermylen J. Acute hepatitis A in patients with haemophilia A. Lancet 1993;341:179
46. Mannucci P, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvents and detergent to inactivate virus. Ann Intern Med 1994;120:1201-7
47. Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994;343:211-2
48. Lyon DJ, Chapman C, Martin C, et al. Symptomatic parvovirus B19 infection and heat-treated Factor IX concentrate. Lancet 1989;i:1085
49. Schulman S, Lindgren ACh, Petrini P, Allander T. Transmission of Hepatitis C with pasteurized factor VIII. Lancet 1992;340:305-6
50. Hoofnagle JH, Gerety RJ, Barker LF. Antibody to the Hepatitis B surface antigen in immune serum globulin. Transfusion 1975;15:407-13
51. Zuck TF, Preston MS. Evidence suggesting that immune globulin preparations do not transmit AIDS. In: Petricciani JC, Gust ID, Hoppe PA, Krinjen HW, eds. AIDS; The Safety of Blood and Blood Products. New York: John Wiley, 1987;93-101.
52. Tedder RS, Uttley A, Cheingsong-Popov R. Safety of immunoglobulin preparation containing anti-HTLV-III. Lancet 1985;i:815
53. Yu MYW, Mason BL, Tankersley DL. Detection and characterization of Hepatitis C virus RNA in immune globulins. Transfusion 1994;34:596-602
54. Navarro V, Guix J, Bernacer B, et al. Tuberculosis and human immunodeficiency virus infection. A prospective study of 215 patients. Rev Clin Esp 1998;192:315-20
55. WHO. Utilization and supply of human blood and blood products, Document A28/WP/6 (May 1975)
56. Picard A. The Gift of Death, Confronting Canada's Tainted Blood Tragedy. Montreal: Harper Collins, 1995;195-207
57. Leveton L, Sox HC, Stoto MA. The U.S. Blood Supply System in HIV and Blood Supply. (An Analysis of Crisis Decision Making). Washington, DC: Institute of Medicine National Academy Press, 1995;25-55
58. Van Aken WR. The collection and use of human blood and plasma in Europe. Report for the Council of Europe and the Commission of the European Communities CEC-CE-FD(92)
59. Ness P, Pennington R. Plasma fractionation in the United States. A review for clinicians. JAMA 1974;230:247-50
60. Hagen P. Blood - gift or merchandise?. Alan R Liss: USA, 1982;63-77
61. Le Coney. Plasma used by US fractionators was exclusively obtained through plasmapheresis. Plasma Quarterly, September 1980
62. Reasor J. Plasma Quarterly, March 1981
63. Aledort L. The availability of plasma products and the care of hemophilia patients. JAMA 1981;46:157
64. Volkow P. Transmisión por vía sanguínea del VIH/SIDA en America Latina. Implicaciones legislatives para la prevención In: Izazola-Licea JA, ed. Políticas Públicas y Prevensión del VIH/SIDA en América Latina y el Caribe. México, DF: Fundación Mexicana para la Salud AC, 2001; 91-115
65. Jurgens A, Bezuidenhout J. SA used as artery in National dodgy blood scandal. Sunday Times South Africa 13 August 2000
66. Kumar S. Austria investigates allegations of tainted-blood exports. Lancet 2000;356:920-22.
67. Michael L. Selling of tainted blood spreads disease in China. Washington Post, 18 February 1999
68. Wu Z, Rou K, Detels R. Prevalence of HIV infection among former commercial plasma donors in rural eastern China. Health Policy Plan 2001;16:41-6
69. Wehrfitz G. China: The blood market. Newsweek 1996;128:24-8
70. Rosenthal E. Scientists warn of inaction as AIDS spreads in China. The New York Times, 2 August 2000
71. Laris M. Selling of tainted blood spreads disease in China. Washington Post, 18 February 1999
72. Kurtenbach E. China's blood dealers still supplying tainted blood. Beijing AP, October 1997
73. Pomfret J. The high cost of selling blood. Washington Post [www.washingtonpost.com] (1 November 2001)